
The Swiss company Nycomed has taken a big step closer to marketing their drug Revestive for the treatment of adult patients with SBS, or short bowel syndrome, in Europe, after the EMA has recommended the approval of the drug to the European Commision, according to Dagens Pharma.
Nycomed is thus ready to launch the first medical treatment of this rare, but seriously debilitating condition in Europe.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app